Learn More
BACKGROUND Infants born at 33 through 35 completed weeks of gestation (33-35GA) are at risk for severe respiratory syncytial virus (RSV) infection, and palivizumab prophylaxis lowers hospitalizations(More)
Michelle Barton MBBS and Michael Hawkes MDCM (Co-Principal Authors) Dorothy Moore PhD, MD John Conly MD* (Corresponding author) Lindsay Nicolle MD Upton Allen MBBS Nora Boyd RN Joanne Embree MD Liz(More)